Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

352 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, Mitry E, Biagi JJ, Evesque L, Artru P, Lecomte T, Assenat E, Bauguion L, Ychou M, Bouché O, Monard L, Lambert A, Hammel P; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. Conroy T, et al. JAMA Oncol. 2022 Nov 1;8(11):1571-1578. doi: 10.1001/jamaoncol.2022.3829. JAMA Oncol. 2022. PMID: 36048453 Free PMC article. Clinical Trial.
[Clinical practice guideline: 2003 update of Standards, Options et Recommendations for first line palliative chemotherapy in patients with metastatic colorectal cancer (summary report)].
Conroy T, Gory-Delabaere G, Adenis A, Bosquet L, Bouché O, Louvet C, Mitry E, Bécouarn Y, Bosset JF, Ducreux M, Etienne PL, Merrouche Y, Monges G, Rougier P; Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC); Fédération Hospitalière de France (FHF); Fédération Nationale de Cancérologie des Centres Hospitaliers Régionaux et Universitaires (FNCCHRU); Fédération Française de Cancérologie des Centres Hospitaliers Généraux (FFCCHG); Centres Régionaux de Lutte Contre le Cancer (CRLCC); Fédération Française de Cancérologie Digestive (FFCD); Société Nationale Française de Gastro-Entérologie (SNFGE); Groupe coopérateur multidisciplinaire en oncologie (Gercor). Conroy T, et al. Bull Cancer. 2004 Oct;91(10):759-68. Bull Cancer. 2004. PMID: 15556876 Free article. French.
Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study.
Conroy T, Paillot B, François E, Bugat R, Jacob JH, Stein U, Nasca S, Metges JP, Rixe O, Michel P, Magherini E, Hua A, Deplanque G. Conroy T, et al. J Clin Oncol. 2005 Feb 20;23(6):1228-36. doi: 10.1200/JCO.2005.06.050. J Clin Oncol. 2005. PMID: 15718320 Clinical Trial.
[Clinical Practice Guidelines 2004. Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach: radiotherapy (therapeutic evaluation)].
Ychou M, Gory-Delabaere G, Blanc P, Bosquet L, Duffour J, Giovannini M, Guillemin F, Lemanski C, Marchal F, Masson B, Merrouche Y, Monges G, Adenis A, Bosset JF, Bouché O, Conroy T, Pezet D, Triboulet JP; Fédération nationale des centres de lutte contre le cancer (FNCLCC); Fédération hospitalière de France (FHF); Fédération nationale de Cancérologie des CHRU (FNCHRU); Fédération française de cancérologie des CHG (FFCCHG); Centres régionaux de lutte contre le cancer (CRLCC). Ychou M, et al. Among authors: conroy t. Bull Cancer. 2005 Apr;92(4):381-409. Bull Cancer. 2005. PMID: 15888395 Free article. Review. French.
Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: a phase I study.
François E, Ychou M, Ducreux M, Bertheault-Cvitkovic F, Giovannini M, Conroy T, Lemanski C, Thomas O, Magnin V; Groupe Digestif de la Fédération Nationale des Centres de Lutte Contre le Cancer. François E, et al. Among authors: conroy t. Eur J Cancer. 2005 Dec;41(18):2861-7. doi: 10.1016/j.ejca.2005.08.029. Epub 2005 Nov 15. Eur J Cancer. 2005. PMID: 16297614 Clinical Trial.
Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.
Bonnetain F, Bouché O, Conroy T, Arveux P, Raoul JL, Giovannini M, Etienne PL, Mitry E, Seitz JF, Rougier P, Girault C, Bedenne L; FFCD (Fédération Francophone de Cancérologie Digestive). Bonnetain F, et al. Among authors: conroy t. Gastroenterol Clin Biol. 2005 Nov;29(11):1113-24. doi: 10.1016/s0399-8320(05)82175-x. Gastroenterol Clin Biol. 2005. PMID: 16505756 Free article. Clinical Trial.
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L. Gérard JP, et al. Among authors: conroy t. J Clin Oncol. 2006 Oct 1;24(28):4620-5. doi: 10.1200/JCO.2006.06.7629. J Clin Oncol. 2006. PMID: 17008704 Clinical Trial.
Metastatic colorectal cancer.
Bouche O, Conroy T, Michel P, Penna C, Tournigand C. Bouche O, et al. Among authors: conroy t. Gastroenterol Clin Biol. 2006 Sep;30 Spec No 2:2S30-2S42. Gastroenterol Clin Biol. 2006. PMID: 17151561 Free article. Review. No abstract available.
Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer.
Hebbar M, Di Fioré F, Conroy T, Giraud C, Gasnault L, Fournier C, Péreira R, Bouché O, Fournier P, Deligny N, Joly JP, Maes P, Rad E, Michel P, Adenis A. Hebbar M, et al. Among authors: conroy t. Oncology. 2007;73(3-4):185-91. doi: 10.1159/000127385. Epub 2008 Apr 16. Oncology. 2007. PMID: 18418011
352 results